Influenza virus vaccine - Sinovac Biotech

Drug Profile

Influenza virus vaccine - Sinovac Biotech

Alternative Names: Anflu; Influenza Vaccine (Split Virion), Inactivated - Sinovac Biotech; Split influenza virus vaccine - Sinovac Biotech

Latest Information Update: 20 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sinovac Biotech
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 23 Mar 2015 The vaccine is approved in Hong Kong and is awaiting approval in India for influenza virus infections
  • 14 Aug 2014 Launched for Influenza virus infections (Prevention) in Mexico before August 2014 (IM)
  • 01 Jun 2014 Sinovac completes a phase IV trial in Influenza virus infections (Prevention, 2013-2014 season) in China (NCT02269852)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top